Korea's Ministry of Food and Drug Safety (MFDS) announced on November 3, 2026 that it had approved the imported orphan medicine Vanrafia film-coated tablets, 0.75 mg (atrasentan hydrochloride). The indication described in its Korean press reference is narrower than “all patients with IgA nephropathy”: it is for adults with primary IgA nephropathy whose urine protein-to-creatinine ratio (UPCR) is at least 1.5 g/g. Approval is an important regulatory step, but the notice does not itself establish when the product can be obtained, whether a particular hospital can prescribe it, or what Korean National Health Insurance will pay. The cover is a staged AI-generated concept image, not a photograph of the approved product.
Check the exact diagnosis and measurement
IgA nephropathy can involve deposition of immunoglobulin A in the kidney's filtering units and may damage kidney function over time. The MFDS release specifies primary IgA nephropathy, meaning the disease is not being described as secondary to another condition. It also specifies adults and a numeric UPCR threshold of 1.5 g/g. UPCR compares protein and creatinine in urine; it is not interchangeable with every other way a laboratory may report proteinuria. Someone looking at a result should check the test date, the name of the measurement and its units before comparing it with the approval statement.
These criteria are a starting point for a discussion, not a self-prescribing rule. A nephrologist must consider the diagnostic record, recent tests, kidney function, existing therapies and the full current product information. A result near or above the headline threshold alone cannot answer whether this medicine is appropriate or safe for a particular person. Do not stop an existing medicine or change a treatment plan on the strength of the press release or this article.
What the approval does—and does not—show
MFDS describes atrasentan as selectively blocking the endothelin A receptor, a pathway involved in kidney damage. The release says the treatment reduces proteinuria and delays progression of kidney-function decline. That is a regulatory communication about the medicine's intended effects; it is not a guarantee of cure, a specific benefit for every patient, or a promise that kidney failure or dialysis will be avoided. MFDS also says the product was designated No. 53 under GIFT, its expedited-review support scheme. Faster regulatory review is not evidence of stock at a pharmacy today.
Four questions need separate answers: Was the product approved? Is it being supplied domestically? Can a particular institution prescribe or dispense it now? Is it covered by National Health Insurance under criteria that this patient meets? The November 3 press reference answers the first question, but does not give a launch date, a list of prescribing facilities, a reimbursement decision, or a patient co-payment. “Imported orphan medicine” is not a substitute for any of those details. Insurance criteria may also differ from the wording of the marketing authorization if and when coverage is established.
A practical sequence for the next appointment
Bring the latest urine test and relevant clinical records to a nephrology appointment. Ask whether the recorded diagnosis is primary IgA nephropathy and whether the laboratory has reported UPCR in g/g. If the basic indication appears relevant, ask the clinician to review the current product authorization and prescribing information against your other conditions and medicines. A short news release is not a complete guide to dosing, tests before treatment, contraindications, drug interactions or adverse reactions. Discuss patient-specific factors, including pregnancy-related considerations or other organ conditions where relevant, with the treating team rather than relying on a general summary.
Then ask the hospital's pharmacy or prescribing service whether the product is actually available and when prescribing can begin. For cost, request a current, dated check of National Health Insurance coverage, any applicable eligibility conditions and expected out-of-pocket payment from the hospital's billing or pharmacy team or the responsible insurance information service. Coverage and supply can change after an authorization; an older search result may be misleading. If the hospital cannot yet confirm availability or payment, keep those answers explicitly unresolved rather than treating approval as an immediate treatment appointment.
The MFDS announcement does not create a patient application deadline or a universal enrollment process. There is no reason to seek an unofficial seller or abandon established care because of the approval headline. The useful next steps are to verify diagnosis and UPCR, discuss individual suitability with a nephrologist, and check supply and reimbursement separately. Revisit MFDS's product-specific authorization and your clinical provider's current guidance if later notices change the picture.
About the Author
The Life Mokcha editorial team reviews official announcements and primary sources to explain practical information. Check the linked original sources for applicable terms and later updates.
